|Bid||5,900.00 x 6100|
|Ask||6,150.00 x 13000|
|Day's Range||5,981.00 - 6,103.00|
|52 Week Range||5,110.00 - 6,540.00|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||32.05|
|Forward Dividend & Yield||2.15 (3.76%)|
|1y Target Est||N/A|
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a...
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
AstraZeneca (ZN) needs a blockbuster to justify its nearly $7 billion investment for a share of Japan-based Daiichi Sankyo's (TSE:4568) drug to treat a type of breast cancer. Warning! GuruFocus has detected 5 Warning Signs with AZN. The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with another drug combination.
AstraZeneca Plc’s first-ever stock sale has been a painful experience. The British drugmaker was exploiting its strong share price to get its financial house in order. Right now, its free cash flow isn’t enough to cover the dividend without some help from disposals.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Lynparza’s first-quarter performance In the first quarter, AstraZeneca’s (AZN) Lynparza sales rose 99% YoY (year-over-year) to $237 million on a reported
Viral immunotherapy represents a new way of treating cancer by using transgenes, or genes that are artificially introduced into the genome of another organism. "AstraZeneca will select the transgenes to be encoded within the virus and will be responsible for further in-vivo pre-clinical development and, subject to option exercise, clinical development and commercialisation of these novel oncolytic immunotherapies," Transgene said. AstraZeneca has been moving deeper into cancer therapy market through wide-ranging deals, including those for immunotherapy and targeted therapy.
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Imfinzi’s first-quarter performanceIn the first quarter, AstraZeneca’s (AZN) Imfinzi saw sales of $295 million, mainly driven by its rapid uptake as an
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Tagrisso’s first-quarter performanceIn the first quarter, AstraZeneca’s (AZN) Tagrisso sales rose 86% YoY (year-over-year) to $630 million on a reported basis
BenevolentAI is an AI company where AI actually means something. Founded in 2013, it focuses on "accelerating the journey from data to medicines." To achieve that, it has raised a whopping $202 million to look at early drug discovery through to late-stage clinical development, and has a research facility in Cambridge, U.K. where there is plenty of AI talent to be had. Today it has inked a long-term collaboration with pharma giant AstraZeneca to use AI and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Expense guidanceIn its first-quarter press release, AstraZeneca (AZN) guided for its fiscal 2019 core operating expenses rising YoY (year-over-year) by a low
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for AstraZeneca PLC (LON:AZN) reflect what it's really worth? Today, we will...
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)EPS guidance In its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for core EPS of $3.50–$3.70 in fiscal 2019. The company expects its YoY
How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Revenue guidanceIn its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for high-single-digit percentage growth in its fiscal 2019 product
U.S. President Donald Trump will meet with congressional Democratic leaders soon to discuss drug prices, the White House said on Tuesday following infrastructure talks with House Speaker Nancy Pelosi and Senate Democratic leader Chuck Schumer. The White House said in a statement that the three agreed to meet "in the near future" over the health issue and that Trump "feels there is a long way to go" to lower drug costs, without elaborating.
How AstraZeneca Is Looking after Its First-Quarter ResultsStock price movement On April 26, AstraZeneca (AZN) announced its first-quarter results. Its revenue rose 6% YoY (year-over-year) to $5.49 billion on a reported basis and 11% on a CER
These A-list drugmakers must both contend with expiring patents, new drug uncertainties, and hungry competitors. But they're in different stages of their cyclical journeys.
NextCure Inc., a Beltsville biotech with one anticancer drug in clinical testing and several local biotech veterans in its leadership ranks, has filed to go public three years after its founding. The company, which has applied to trade on the Nasdaq Global Market under the ticker symbol "NXTC," plans to offer 5 million shares to the public, with up to 750,000 additional shares available to its underwriters. It estimates an offering price of $14 to $16 per share, bringing a potential total haul to $80.5 million to $92 million if all shares are sold in the initial public offering.
Early Friday, AstraZeneca earnings of 89 cents a share on $5.47 billion in sales beat forecasts. AstraZeneca raised profit guidance for 2019, but AstraZeneca stock dipped.
Newer treatments such as lung cancer drug Tagrisso, now the company's top selling medicine, have helped the drugmaker's return to growth after years of crumbling sales due to patent losses on older drugs. Sales in China have shown explosive growth, more than doubling since 2012, but AstraZeneca executives on Friday said that may not be sustained. "The enormous growth you currently see in China, 28 percent, probably is not sustainable, but we feel very bullish that the growth will continue to be at a pace of between 15 percent and 20 percent," Ruud Dobber, executive vice president, BioPharma, told Reuters.
LONDON (AP) — Anglo-Swedish drugmaker AstraZeneca says first quarter earnings jumped 74%, buoyed by emerging markets and the success of new cancer treatments.